The SUM-1315MO2 cell line is clearly the most unusual of the SUM series of breast cancer cell lines. This cell line was derived from the second transplant generation of a mouse primary xenograft tumor that was established at the NIH from a patient with a highly aggressive form of breast cancer, charactarized by extensive dermal invasion and metastasis. The NIH lab failed to develop a cell line from these cells and so they provided tubes of cells to our lab which we used to establish the cell line. In establishing this cell line, we found that these cells underwent rapid apoptosis in the presence of hydrocortisone, which we normally used in all of our media. In addition, these cells required EGF in the medium to grow. Thus, SUM-1315MO2 cells grow in a serum-free medium with insulin and EGF, but without hydrocortisone.
Okay, let’s delve more deeply into the SUM-1315 cell line.
- Derivation of the SUM-1315 cell line
- The oncogenes of the SUM-1315 cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- The functional-druggable signature for SUM1315 cells
- Differential drug sensitivity data from Heiser et al.
- Bibliography of published papers in which SUM-1315 cells were used
- SUM-1315 Blog
Back to the SUM cell line Gateway Page
